Clinical Verification of Peptide Biomarkers for Human Aging

Clinical Verification of Peptide Biomarkers for Human Aging by Standard-Free, Label-Free LC-MS/MS Quanification of Aldehyde-modified Peptides

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT02166307

Enrollment

253

Registered

2014-06-18

Start date

2009-01-31

Completion date

2011-12-31

Last updated

2014-06-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Aging

Keywords

formaldehyde; Maillard Reaction; cross-linkage; human aging

Brief summary

Aging in human physically refers to a multidimensional process that all the changes were accumulated in a person over time. These aging changes are responsible for the progressive increases in the chance of disease and death associated with them. So far, there are several theories have been developed to understand the aging process, such as cross-linking, which is led by Maillard Reactions. Maillard Reaction is a complex series of reactions between reducing sugar/aldehydes and amino groups on proteins. Under physiological conditions, aldehydes are products of various exogenous and endogenous amines catalyzed by semicarbazide-sensitive amine oxidase (SSAO), a family of heterogeneous enzyme. It was reported that SSAO shows a significant higher catalytic activity, producing more aldehydes in age-related diseases. However, SSAO is not a perfect candidate to be monitored for evaluating aging, because it is widely distributed in tissues, which are not readily accessible sample-sources for clinical applications. In this work, the investigators have found 6 biomarker candidates by developing a standard-free, label-free MS-based proteomics method based on standard protein (human serum albumin, the highest abundance protein in human plasma) model in vitro. Then, the investigators wanted to verify these biomarker candidates by clinical plasma samples to see if there is significant quantitative difference among people with different ages.

Detailed description

The procedure of clinical study was: 1. to get plasma samples from hospital; 2. digestion of plasma protein-mixture by trypsin in lab; 3. run mass spectrometry and monitor the amount of target HSA-peptides.

Interventions

None listed

Study design

Observational model

CASE_ONLY

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

23 Years to 72 Years

Healthy volunteers

Yes

Inclusion criteria

* Cases with different ages

Exclusion criteria

* Cases with Diabetes Mellitus and Hepatitis B

Design outcomes

Primary

Measure	Time frame	Description
measurement of the amount of plasma peptides	two years	The investigators have found 6 biomarker candidates by developing a standard-free, label-free MS-based proteomics method based on standard protein (human serum albumin, the highest abundance protein in human plasma) model in vitro. Then, the investigators wanted to verify these biomarker candidates by clinical plasma samples to see if there is significant quantitative difference among people with different ages.

Outcome results